A patient with stage 4 chronic kidney disease presents with elevated potassium and phosphate levels, as well as increased parathyroid hormone (PTH) levels. Which nursing intervention should be prioritized to address the most immediate risk to the patient?

C) Implement potassium-reducing strategies to prevent cardiac complications.

A) Educate the patient on a low-phosphate diet to manage hyperphosphatemia.

B) Administer prescribed phosphate binders to reduce serum phosphate levels.

C) Implement potassium-reducing strategies to prevent cardiac complications.

D) Monitor and document the patient's fluid intake and output accurately.

A patient with stage 4 chronic kidney disease (CKD) presents with elevated potassium and phosphate levels, secondary hyperparathyroidism, and worsening renal function. Which nursing intervention is most appropriate to address the risk of cardiac complications?

B) Initiate a low-potassium diet.

A) Administer calcium carbonate to bind phosphate.

B) Initiate a low-potassium diet.

C) Prepare the patient for hemodialysis.

D) Educate the patient on fluid restriction.

A patient with stage 4 CKD is admitted with acute shortness of breath, worsening peripheral edema, and recent weight gain. The assessment reveals bilateral crackles, elevated blood pressure, and a decrease in GFR to 25 mL/min/1.73 m². What is the priority nursing intervention for this patient?

C) Initiate oxygen therapy to improve oxygen saturation.

A) Administer prescribed oral diuretics to reduce fluid overload.

B) Elevate the patient's legs to decrease peripheral edema.

C) Initiate oxygen therapy to improve oxygen saturation.

D) Restrict dietary sodium to manage blood pressure.

A patient with stage 4 CKD has been admitted with acute shortness of breath and peripheral edema. The patient's GFR is 25 mL/min/1.73 m², and there is evidence of pulmonary congestion and pleural effusions. Which nursing intervention is most important to prioritize in managing this patient's fluid overload?

B) Administer the prescribed intravenous diuretics and monitor urine output closely.

A) Encourage increased oral fluid intake to flush the kidneys.

B) Administer the prescribed intravenous diuretics and monitor urine output closely.

C) Place the patient in Trendelenburg position to improve oxygenation.

D) Restrict the patient's sodium intake to less than 2 grams per day.

A patient with chronic kidney disease (CKD) and heart failure is being treated with intravenous furosemide and an angiotensin receptor blocker (ARB). Despite an improvement in peripheral edema, the patient continues to experience elevated blood pressure and tachycardia. Which nursing intervention is most appropriate to address the patient's ongoing hypertension and contribute to improved cardiac function?

A) Educate the patient about the importance of adhering to a low-sodium diet.

B) Increase the frequency of furosemide administration.

C) Encourage the patient to perform daily weight monitoring.

D) Suggest the patient increase fluid intake to improve renal function.

A patient with chronic kidney disease (CKD) and hypertension is being treated with intravenous furosemide for fluid overload. Despite initial improvement, the patient's blood pressure remains elevated, and tachycardia persists. The healthcare team plans to add an angiotensin receptor blocker (ARB) to the treatment regimen. What is the primary rationale for adding an ARB in this clinical scenario?

C) To protect renal function and aid in managing hypertension.

A) To directly decrease heart rate and manage tachycardia.

B) To improve fluid excretion by enhancing diuretic effect.

C) To protect renal function and aid in managing hypertension.

D) To correct metabolic acidosis by balancing electrolytes.

A patient with hypertension and chronic kidney disease has recently developed dizziness and fatigue after starting an angiotensin receptor blocker (ARB). Their blood pressure is 95/60 mmHg, and creatinine levels have increased to 2.5 mg/dL. What is the priority nursing intervention?

B) Continue monitoring the patient's blood pressure and withhold the ARB temporarily.

A) Administer prescribed erythropoiesis-stimulating agents to address the anemia.

B) Continue monitoring the patient's blood pressure and withhold the ARB temporarily.

C) Increase fluid intake to improve renal perfusion and raise blood pressure.

D) Administer potassium supplements to correct the serum potassium level.

A patient with a recent addition of an angiotensin receptor blocker (ARB) presents with dizziness, fatigue, and a blood pressure of 95/60 mmHg. Laboratory results indicate persistent metabolic acidosis, slightly increased creatinine levels, and mild anemia. What is the most appropriate nursing intervention to address the patient's current condition?

B) Hold the ARB medication and monitor blood pressure and renal function closely.

A) Administer intravenous fluids to increase blood pressure and improve renal perfusion.

B) Hold the ARB medication and monitor blood pressure and renal function closely.

C) Administer erythropoiesis-stimulating agents to treat the anemia and improve symptoms.

D) Increase dietary potassium to address the patient's serum potassium level.

A patient with chronic kidney disease presents with metabolic acidosis, evidenced by a pH of 7.32, partial pressure of carbon dioxide at 36 mmHg, and bicarbonate level at 19 mmol/L. The healthcare team plans to start low-dose bicarbonate therapy. Which clinical finding would indicate that the therapy is effective?

C) Normalization of the blood pH

B) Improved renal ultrasound results

C) Normalization of the blood pH

D) Decreased partial pressure of carbon dioxide

A patient with chronic kidney disease presents with metabolic acidosis, as indicated by an arterial blood gas showing a pH of 7.32, PaCO2 of 36 mmHg, and bicarbonate of 19 mmol/L. The healthcare team has initiated low-dose bicarbonate therapy. Which of the following nursing interventions is most appropriate to monitor the effectiveness of this treatment?

C) Check the patient's serum bicarbonate and arterial blood gas levels.

A) Monitor the patient's blood pressure regularly.

B) Assess the patient's skin turgor and mucous membranes.

C) Check the patient's serum bicarbonate and arterial blood gas levels.

D) Measure the patient's urine output every hour.

CKD - Nursing Case Study

Pathophysiology

• Primary mechanism: Chronic kidney disease (CKD) primarily results from prolonged damage to the nephrons, often due to diabetes or hypertension. This damage reduces the kidneys' ability to filter waste and balance fluids and electrolytes, leading to progressive loss of renal function.

• Secondary mechanism: Persistent nephron damage triggers compensatory hyperfiltration in remaining functional nephrons. This increases glomerular pressure, further injuring these nephrons and accelerating renal function decline.

• Key complication: As CKD progresses, the inability to excrete phosphate leads to hyperphosphatemia, which, along with decreased active vitamin D production, results in secondary hyperparathyroidism. This imbalance can cause bone disease and vascular calcification, impacting patient health.

Patient Profile

Demographics:

56-year-old male, construction worker

History:

• Key past medical history: Hypertension for 10 years, type 2 diabetes for 7 years

• Current medications: Lisinopril, Metformin, Atorvastatin

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasing fatigue and swelling in the legs

• Key symptoms: Decreased urine output, mild shortness of breath, occasional dizziness

• Vital signs: Blood pressure 148/92 mmHg, heart rate 88 bpm, respiratory rate 20 breaths per minute, temperature 98.6°F, SpO2 92% on room air

Section 1

New Diagnostic Results:

In response to the patient's increasing fatigue, swelling, and decreased urine output, further diagnostic tests were conducted to evaluate the progression of his chronic kidney disease. Recent laboratory results revealed a significant decline in renal function, with a glomerular filtration rate (GFR) dropping to 28 mL/min/1.73 m², indicating stage 4 CKD. Serum creatinine levels were elevated at 2.9 mg/dL, while blood urea nitrogen (BUN) was found to be 42 mg/dL, suggesting worsening kidney function. Electrolyte imbalances were also noted, with elevated serum potassium at 5.6 mmol/L and serum phosphate at 5.2 mg/dL, indicative of hyperphosphatemia. Additionally, the patient’s parathyroid hormone (PTH) level was markedly increased, confirming secondary hyperparathyroidism.

These diagnostic findings highlight the progression of CKD and the development of related complications, including electrolyte imbalances and secondary hyperparathyroidism. The elevated potassium level raises concerns about potential cardiac complications, necessitating careful monitoring and management to prevent life-threatening arrhythmias. The increase in phosphate and PTH levels also underscores the need for interventions aimed at managing bone mineral disorders. The patient’s current medication regimen may require adjustment, including the potential addition of phosphate binders and vitamin D analogs to better control these metabolic derangements.

The new diagnostic results provide a clearer picture of the patient's deteriorating renal function and associated complications. This information is critical for guiding treatment decisions, such as potential dietary modifications, medication adjustments, and consideration of future renal replacement therapy options. The healthcare team must now focus on a comprehensive management plan that addresses not only the immediate complications but also the long-term progression of CKD, with an emphasis on improving the patient's quality of life and preventing further decline.

Section 2

Change in Patient Status:

In the weeks following the adjustment of the patient's treatment plan to address the complications of stage 4 CKD, the patient was admitted to the hospital due to acute shortness of breath and worsening peripheral edema. On initial examination, vital signs showed a blood pressure of 160/95 mmHg, heart rate of 105 beats per minute, respiratory rate of 24 breaths per minute, and oxygen saturation of 89% on room air. Lung auscultation revealed bilateral crackles, particularly in the lower lung zones, suggesting fluid overload. Further examination indicated pitting edema extending to the knees, and the patient reported a weight gain of 5 kg over the past week.

A chest X-ray was performed, revealing pulmonary congestion and pleural effusions, consistent with volume overload. Repeat laboratory tests showed further deterioration in renal function, with a GFR now at 25 mL/min/1.73 m². Serum potassium remained elevated at 5.8 mmol/L, and a new finding of mild metabolic acidosis was noted with a bicarbonate level of 18 mmol/L. The patient's cardiac markers were within normal limits, ruling out an acute coronary syndrome. The clinical picture suggested that the patient was experiencing acute decompensated heart failure secondary to fluid overload, likely exacerbated by the declining kidney function and inadequate response to current diuretic therapy.

These findings necessitated an immediate and coordinated approach to manage the acute heart failure symptoms and prevent further complications. The healthcare team discussed the potential need for more aggressive diuresis, possibly through intravenous diuretics, and considered the initiation of renal replacement therapy as the patient's condition continued to decline. The situation also prompted a reevaluation of the long-term management plan, emphasizing the importance of closer monitoring of fluid status, electrolyte balance, and cardiac function to prevent future episodes. The patient's treatment regimen was further adjusted, incorporating dietary sodium and fluid restrictions, alongside a potential escalation of pharmacological interventions.

Section 3

Response to Interventions:

Following the initial assessment, the healthcare team initiated treatment by administering intravenous furosemide to aggressively manage the fluid overload. Over the next 48 hours, the patient showed some signs of improvement. The peripheral edema reduced slightly, and there was a decrease in the patient's weight by approximately 2 kg, indicating a positive diuretic response. The patient's breathing became easier, with oxygen saturation levels improving to 93% on room air. However, despite these improvements, the patient's blood pressure remained elevated at 155/90 mmHg, and tachycardia persisted with a heart rate of 100 beats per minute. This raised concerns about ongoing fluid retention and the potential need for further intervention.

Laboratory results after diuretic therapy showed a slight reduction in serum potassium to 5.5 mmol/L, but the metabolic acidosis persisted with a bicarbonate level of 19 mmol/L. Additionally, a follow-up echocardiogram revealed mild left ventricular hypertrophy and reduced ejection fraction at 40%, consistent with chronic changes due to the underlying CKD and hypertension. These findings prompted consideration of modifying the patient's medication regimen to address the hypertension and cardiac function more effectively.

The healthcare team decided to adjust the patient's treatment plan by adding an angiotensin receptor blocker (ARB) to help manage blood pressure and protect renal function further. They also emphasized the importance of strict adherence to dietary restrictions, including low sodium and potassium intake, to prevent exacerbation of heart failure symptoms. The team planned for close monitoring of the patient's renal function, electrolyte levels, and cardiac status, with a follow-up appointment scheduled to evaluate the effectiveness of the revised treatment strategy. The patient's response to these interventions would be critical in determining the next steps in managing their complex condition.

Section 4

New Complications:

Despite the adjustments in the patient's treatment plan, new complications emerged over the subsequent days. The patient began experiencing episodes of dizziness and fatigue, which led to a reassessment by the healthcare team. Vital signs showed a blood pressure of 95/60 mmHg, indicating a significant drop from previous readings, and a heart rate of 88 beats per minute. This hypotensive episode raised concerns about the recent addition of the angiotensin receptor blocker and the need to re-evaluate the patient's antihypertensive regimen.

Laboratory tests showed a further decrease in serum potassium to 4.2 mmol/L, which was within normal limits, but the metabolic acidosis persisted, with a bicarbonate level remaining at 19 mmol/L. Additionally, the patient's renal function tests revealed a slight increase in creatinine levels to 2.5 mg/dL, suggesting a potential compromise in renal perfusion due to the lower blood pressure. Mild anemia was also noted, with a hemoglobin level of 10.5 g/dL, possibly contributing to the patient's fatigue and dizziness. These findings necessitated a careful reconsideration of the balance between blood pressure control and renal function preservation.

The healthcare team decided to temporarily hold the ARB and closely monitor the patient's blood pressure and renal function. Education was reinforced regarding the importance of reporting symptoms such as dizziness or fatigue promptly. The team emphasized the need for further diagnostic evaluation to assess the underlying causes of the metabolic acidosis and consider potential treatments for the anemia, such as erythropoiesis-stimulating agents. The patient's journey now focused on stabilizing these new complications while maintaining vigilance for any further changes in their condition.

Section 5

As the healthcare team continued to monitor the patient's condition, new diagnostic results provided further insights into the underlying issues. An arterial blood gas test was conducted to evaluate the severity of the metabolic acidosis. The results showed a pH of 7.32, a partial pressure of carbon dioxide at 36 mmHg, and a bicarbonate level holding steady at 19 mmol/L. These findings confirmed a persistent metabolic acidosis with partial respiratory compensation. The team hypothesized that the acidosis could be a result of the decreased renal function and the body's inability to excrete acid effectively. Additionally, a repeat complete blood count indicated that the mild anemia had slightly worsened, with the hemoglobin level now at 10 g/dL, which was consistent with the patient's ongoing fatigue and dizziness.

Further diagnostic imaging, including a renal ultrasound, was ordered to assess for any structural abnormalities or evidence of acute kidney injury that could be contributing to the decreased renal perfusion. The ultrasound revealed no significant changes in kidney structure but did show signs of mild renal parenchymal disease, which aligned with the clinical picture of chronic kidney disease progression. Given these findings, the healthcare team considered the need for renal biopsy to better understand the etiology of the worsening kidney function, although this was weighed against the potential risks for the patient.

Based on the diagnostic results, the healthcare team decided to initiate a low-dose bicarbonate therapy to address the metabolic acidosis, while continuing to hold the ARB to prevent further hypotension. They also discussed the initiation of an erythropoiesis-stimulating agent to manage the anemia and improve the patient's energy levels. The patient's response to these interventions would be closely monitored, with plans to adjust the treatment regimen as needed to balance renal function preservation with symptom management. This stage of the patient's journey emphasized the importance of integrated care and ongoing assessment to navigate the complexities of chronic kidney disease amidst evolving complications.